Castro, E, Wang, D, Walsh, S, Craigie, S, Haltner, A, Nazari, J, Niyazov, A, Samjoo, IA (2024).
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison
PROSTATE CANCER AND PROSTATIC DISEASES. Article.
[doi:10.1038/s41391-024-00924-x]
Esteban-Villarrubia, J, Ballesteros, PA, Martín-Serrano, M, Vico, MR, Funes, JM, de Velasco, G, Castro, E, Olmos, D, Castellano, D, González-Billalabeitia, E (2024).
Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer
Immuno. Review. 4(4):444-460.
[doi:10.3390/immuno4040028]
Castro, E, Figliuzzi, R, Walsh, S, Craigie, S, Nazari, J, Niyazov, A, Samjoo, IA (2024).
Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer
ONCOLOGIST. Review.
[doi:10.1093/oncolo/oyae321]
Manso, LS, Alfranca, A, Moreno-Pérez, I, Ruiz-Vico, M, Velasco, C, Toquero, P, Pacheco, M, Zapatero, A, Aldave, D, Celada, G, Albers, E, de la Maza, MDF, García, J, Castro, E, Olmos, D, Colomer, R, Romero-Laorden, N (2024).
Immunome profiling in prostate cancer: a guide for clinicians
Frontiers in immunology. Review. 15:1398109-1398109.
[doi:10.3389/fimmu.2024.1398109]
van de Haar, J, Roepman, P, Andre, F, Balmaña, J, Castro, E, Chakravarty, D, Curigliano, G, Czarnecka, AM, Dienstmann, R, Horak, P, Marchiò, C, Italiano, A, Monkhorst, K, Pritchard, CC, Reardon, B, Russnes, HEG, Sirohi, B, Sosinsky, A, Spanic, T, Turnbull, C, Van Allen, E, Westphalen, CB, Tamborero, D, Mateo, J (2024).
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
ANNALS OF ONCOLOGY. Article. 35(11):954-967.
[doi:10.1016/j.annonc.2024.06.018]
Castro, E, Ellis, J, Craigie, S, Haltner, A, Nazari, J, Niyazov, A, Samjoo, IA (2024).
Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer
ONCOLOGIST. Review. 30(3).
[doi:10.1093/oncolo/oyae237]
Montero-Hidalgo, AJ, Jiménez-Vacas, JM, Gómez-Gómez, E, Porcel-Pastrana, F, Sáez-Martinez, P, Pérez-Gómez, JM, Fuentes-Fayos, AC, Blázquez-Encinas, R, Sánchez-Sánchez, R, González-Serrano, T, Castro, E, López-Soto, PJ, Carrasco-Valiente, J, Sarmento-Cabral, A, Martinez-Fuentes, AJ, Eyras, E, Castaño, JP, Sharp, A, Olmos, D, Gahete, MD, Luque, RM (2024).
SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer
Science Advances. Article. 10(40).
[doi:10.1126/sciadv.ado8231]
Samjoo, IA, Disher, T, Castro, E, Ellis, J, Paganelli, S, Nazari, J, Niyazov, A (2024).
Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer
CLINICAL GENITOURINARY CANCER. Review. 22(5):102137-102137.
[doi:10.1016/j.clgc.2024.102137]
Castro, E (2024).
PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers
European Urology Focus. Editorial Material. 10(4):504-505.
[doi:10.1016/j.euf.2024.08.005]
Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, Helfand BT, Talaty P, Ong KR, Douglas E, Cook J, Rosario DJ, Salinas M, Buys SS, Anson J, Davidson R, Longmuir M, Side L, Eccles DM, Tischkowitz M, Taylor A, Cruellas M, Ballestero EP, Cleaver R, Varughese M, Barwell J, LeButt M, Greenhalgh L, Hart R, Azzabi A, Jobson I, Cogley L, Evans DG, Rothwell J, Taylor N, Hogben M, Saya S, Eeles RA, Aaronson NK (2024).
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
BJU INTERNATIONAL. Article. 134(3):484-500.
[doi:10.1111/bju.16432]
Cheng, HH, Shevach, JW, Castro, E, Couch, FJ, Domchek, SM, Eeles, RA, Giri, VN, Hall, MJ, King, MC, Lin, DW, Loeb, S, Morgan, TM, Offit, K, Pritchard, CC, Schaeffer, EM, Szymaniak, BM, Vassy, JL, Katona, BW, Maxwell, KN (2024).
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review
JAMA oncology. Review. 10(9):1272-1281.
[doi:10.1001/jamaoncol.2024.2185]
Mosele, MF, Westphalen, CB, Stenzinger, A, Barlesi, F, Bayle, A, Bieche, I, Bonastre, J, Castro, E, Dienstmann, R, Krämer, A, Czarnecka, AM, Meric-Bernstam, F, Michiels, S, Miller, R, Normanno, N, Reis, J, Remon, J, Robson, M, Rouleau, E, Scarpa, A, Serrano, C, Mateo, J, Andre, F (2024).
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
ANNALS OF ONCOLOGY. Article. 35(7):588-606.
[doi:10.1016/j.annonc.2024.04.005]
Romero-Laorden, N, Lorente, D, de Velasco, G, Lozano, R, Herrera, B, Puente, J, López, PP, Medina, A, Almagro, E, Gonzalez-Billalabeitia, E, Villla-Guzman, JC, González-del-Alba, A, Borrega, P, Laínez, N, Fernández-Freire, A, Hernández, A, Rodriguez-Vida, A, Chirivella, I, Fernandez-Parra, E, López-Campos, F, Pacheco, MI, Morales-Barrera, R, Fernández, O, Villatoro, R, Luque, R, Hernando, S, Castellano, DC, Castro, E, Olmos, D (2024).
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
European Urology Oncology. Article. 7(3):447-455.
[doi:10.1016/j.euo.2023.09.015]
Iglesias-Corral, D, García-Valles, P, Arroyo-Garrapucho, N, Bueno-Martínez, E, Ruiz-Robles, JM, Ovejero-Sánchez, M, González-Sarmiento, R, Herrero, AB (2024).
Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death
Frontiers in oncology. Article. 14:1390518-1390518.
[doi:10.3389/fonc.2024.1390518]
Olmos, D, Lorente, D, Alameda, D, Cattrini, C, Romero-Laorden, N, Lozano, R, Lopez-Casas, PP, Jambrina, A, Capone, C, Vanden Broecke, AM, Trevisan, M, Van Sanden, S, Juergens, A, Herrera-Imbroda, B, Castro, E (2024).
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
ANNALS OF ONCOLOGY. Article. 35(5):458-472.
[doi:10.1016/j.annonc.2024.01.011]
Casadei, C, Scarpi, E, Conteduca, V, Gurioli, G, Cursano, MC, Brighi, N, Lolli, C, Schepisi, G, Basso, U, Fornarini, G, Bleve, S, Farolfi, A, Altavilla, A, Burgio, SL, Giunta, EF, Gianni, C, Filograna, A, Ulivi, P, Olmos, D, Castro, E, De Giorgi, U (2024).
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
European Urology Open Science. Article. 61:44-51.
[doi:10.1016/j.euros.2024.01.015]
Bourlon, MT, Valdez, P, Castro, E (2024).
Development of PARP inhibitors in advanced prostate cancer
Therapeutic Advances in Medical Oncology. Review. 16.
[doi:10.1177/17588359231221337]
de la Maza, MDF, Gracia, JLP, Miñana, B, Castro, E (2024).
PARP inhibitors alone or in combination for prostate cancer
Therapeutic Advances in Urology. Review. 16.
[doi:10.1177/17562872241272929]
Calabrese, M, Saporita, I, Turco, F, Gillessen, S, Castro, E, Vogl, UM, Di Stefano, RF, Carfi, FM, Poletto, S, Farinea, G, Tucci, M, Buttigliero, C (2024).
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer
International Journal Of Molecular Sciences. Review. 25(1).
[doi:10.3390/ijms25010078]
Chávarri-Guerra, Y, Bourlon, MT, Rodríguez-Olivares, JL, Orozco, L, Bazua, D, Rodríguez-Faure, A, Alcalde-Castro, MJ, Castro, E, Castillo, D, Herzog, J, Weitzel, J (2023).
Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer
CLINICAL GENITOURINARY CANCER. Article. 21(5):569-573.
[doi:10.1016/j.clgc.2023.05.012]
Beije, N, Abida, W, Antonarakis, ES, Castro, E, de Wit, R, Fizazi, K, Gillessen, S, Hussain, M, Mateo, J, Morris, MJ, Olmos, D, Sartor, O, Sharp, A, Sweeney, CJ, de Bono, JS (2023).
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
EUROPEAN UROLOGY. Editorial Material. 84(3):253-256.
[doi:10.1016/j.eururo.2023.03.038]
Chi, KN, Sandhu, S, Smith, MR, Attard, G, Saad, M, Olmos, D, Castro, E, Roubaud, G, Gomes, AJPD, Small, EJ, Rathkopf, DE, Gurney, H, Jung, W, Mason, GE, Dibaj, S, Wu, D, Diorio, B, Urtishak, K, del Corral, A, Francis, P, Kim, W, Efstathiou, E (2023).
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
ANNALS OF ONCOLOGY. Article. 34(9):772-782.
[doi:10.1016/j.annonc.2023.06.009]
Smith, MR, Sandhu, S, George, DJ, Chi, KN, Saad, F, Thiery-Vuillemin, A, Stáhl, O, Olmos, D, Danila, DC, Gafanov, R, Castro, E, Moon, H, Joshua, AM, Mason, GE, Espina, BM, Liu, Y, Lopez-Gitlitz, A, Francis, P, Bevans, KB, Fizazi, K (2023).
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
Journal of Managed Care & Specialty Pharmacy. Article. 29(7):758-768.
